Zepbound for Gastroparesis

tirzepatide · Investigational / off-label

Last updated 2026-05-28 15:46 UTC

Zepbound (tirzepatide) is not FDA-approved for gastroparesis, and its use for this condition is off-label/investigational. Research suggests a possible link between tirzepatide and delayed gastric emptying, which may pose risks during upper endoscopy.

AI summary of the sources below.

Drug	Zepbound (tirzepatide)
Condition	Gastroparesis
Approval status	Investigational / off-label
Research papers	2

Zepbound is not FDA-approved for gastroparesis; the research below reflects investigational or off-label study only.

Research on tirzepatide for gastroparesis (2)

Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab · 2024 · 58 citations
Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy. Cureus · 2025 · 0 citations

Search PubMed ↗